Skip to main content

Table 1 Characteristics of eligible trials

From: Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis

Author (Study)

Year

Intervention

Dosage of treatment

Duration (yr)

Number of patients

Follow-up (mo)

Gnant (ABCSG12)

2009

Zoledronic acid

No treatment

4 mg IV every 6 months

3

899

904

47.8

Shapiro (CALGB)

2011

Zoledronic acid

No treatment

4 mg IV every 3 months

NA

70

80

12

Hershman

2008

Zoledronic acid

Placebo

4 mg IV every 3 months

1

50

53

12

Coleman (AZURE)

2011

Zoledronic acid

No treatment

4 mg IV monthly for 6 months, then every 3 months for 8 doses and then every 6 months for 5 doses

5

1665

1675

6

Brufsky (Z-FAST)

2009

Upfront zoledronic acid

Delayed zoledronci acid

4 mg IV every 6 months

5

300

300

36

Eidtmann (ZO-FAST)

2010

Upfront zoledronic acid

Delayed zoledronci acid

4 mg IV every 6 months

5

524

536

36

Hines (N03CC)

2009

Upfront zoledronic acid

Delayed zoledronci acid

4 mg IV every 6 months

5

267

274

12

  1. yr, year; mo, months; IV, intravenous; NA, not available